Giredestrant

Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1].

Product Specifications

CAS Number

[1953133-47-5]

Product Name Alternative

GDC-9545; RG6171

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/giredestrant.html

Purity

99.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OCC(F)(F)CN([C@@H]1C2=C(F)C=C(NC3CN(CCCF)C3)C=C2F)[C@H](C)CC4=C1NC5=C4C=CC=C5

Molecular Formula

C27H31F5N4O

Molecular Weight

522.55

Precautions

H302, H315, H319

References & Citations

[1]C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes